ATM and prostate carcinoma: Other potential targets in prostate cancer that are being assessed in trials include the PI3K–AKT pathway, which is dysregulated in cancers with functional PTEN loss and which can be targeted with drugs such as ipatasertib,164 immunotherapy for the small proportion of patients harbouring MMR mutations, and ATR inhibitors in ATM mutant tumours (eg, the Planette trial [NCT04564027] of ceralasertib in solid tumours with the relevant mutations).